TRPV1 is a potential biomarker for the prediction and treatment of multiple cancers based on a pan-cancer analysis

Abstract

<abstract> <sec><title>Background</title><p> Transient receptor potential cation channel subfamily V member 1 (<italic>TRPV1</italic>) was considered to play pivotal roles in multiple cancers; however, the expression and clinical significance of the <italic>TRPV1</italic> remain unclear, which were explored in this study. </p></sec> <sec><title>Results</title><p> The pan-cancer analysis was performed based on 10,236 samples in 32 cancers. Differential <italic>TRPV1</italic> expression levels were detected in 12 cancers (<italic>p</italic> &lt; 0.05). <italic>TRPV1</italic> demonstrated its conspicuous prognosis significance and prediction effects for some cancers (e.g., lung adenocarcinoma), indicating its potential as a valuable and novel biomarker in treating and predicting cancers. <italic>TRPV1</italic> expression was relevant to DNA methyltransferases, mismatch repair genes, tumor mutational burden, and microsatellite instability. <italic>TRPV1</italic> expression was associated with the immune microenvironment of some cancers, and its roles in different cancers may be mediated by affecting various immune cells. Gene set enrichment analysis discloses the significant relevance of <italic>TRPV1</italic> expression with a series of metabolic and immunoregulatory-related pathways. </p></sec> <sec><title>Conclusions</title><p> This study provided a comprehensive workflow of the expression, clinical significance, and underlying mechanisms of <italic>TRPV1</italic> in pan-cancer. <italic>TRPV1</italic> may be an underlying biomarker for predicting and treating multiple cancer. </p></sec> </abstract>